Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 29Unknown 11Recruiting 6Terminated 4Withdrawn 2Active not recruiting 2

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Colorectal Neoplasms 3Carcinoma, Hepatocellular 3Colonic Neoplasms 2Rectal Neoplasms 1Pancreatic Neoplasms 1Colorectal Cancer Metastatic 1

Interventions

Fluorouracil 11Leucovorin 10Oxaliplatin 9Bevacizumab 6Irinotecan 5Capecitabine 3regorafenib 2aflibercept 2Folfox protocol 2Exercise 2Chemotherapy, Adjuvant 2Cetuximab 2Biopsy 2Atorvastatin 2tucatinib 1trifluridine tipiracil drug combination 1trastuzumab biosimilar HLX02 1sulindac sulfone 1sargramostim 1retrovector encoding mutant anti-cyclin G1 1poly ICLC 1pidilizumab 1pembrolizumab 1p53 peptide 264-272, human 1nilotinib 1monalizumab 1lonafarnib 1irofulven 1infigratinib 1grp protein, Drosophila 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Colonic Neoplasms × Folfox protocol × Clear all
NCT04145193 2020-09-21

Novel Oncology Therapies in Combination With Adjuvant Chemo in High-risk MSS-CRC

MedImmune LLC

Phase 2 Withdrawn
Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms

NCT01270438 2017-04-04

Combination Chemotherapy and Bevacizumab With or Without RO4929097 in Treating Patients With Metastatic Colorectal Cancer

National Cancer Institute (NCI)

Phase 2 Withdrawn
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡